- Home
- CALC vs SNTI Comparison
CALC vs SNTI Comparison
Compare CALC & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- SNTI
- Stock Information
- Founded
- CALC 2011
- SNTI 2016
- Country
- CALC United States
- SNTI United States
- Employees
- CALC N/A
- SNTI N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- CALC Health Care
- SNTI Health Care
- Exchange
- CALC Nasdaq
- SNTI Nasdaq
- Market Cap
- CALC 48.1M
- SNTI 39.6M
- IPO Year
- CALC N/A
- SNTI N/A
- Fundamental
- Price
- CALC $2.91
- SNTI $1.52
- Analyst Decision
- CALC Strong Buy
- SNTI Strong Buy
- Analyst Count
- CALC 2
- SNTI 2
- Target Price
- CALC $14.50
- SNTI $8.50
- AVG Volume (30 Days)
- CALC 91.2K
- SNTI 140.6K
- Earning Date
- CALC 08-12-2025
- SNTI 08-07-2025
- Dividend Yield
- CALC N/A
- SNTI N/A
- EPS Growth
- CALC N/A
- SNTI N/A
- EPS
- CALC N/A
- SNTI N/A
- Revenue
- CALC N/A
- SNTI N/A
- Revenue This Year
- CALC N/A
- SNTI N/A
- Revenue Next Year
- CALC N/A
- SNTI $150.00
- P/E Ratio
- CALC N/A
- SNTI N/A
- Revenue Growth
- CALC N/A
- SNTI N/A
- 52 Week Low
- CALC $1.42
- SNTI $1.46
- 52 Week High
- CALC $5.97
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- CALC 52.85
- SNTI 30.93
- Support Level
- CALC $2.31
- SNTI $1.51
- Resistance Level
- CALC $3.00
- SNTI $1.62
- Average True Range (ATR)
- CALC 0.34
- SNTI 0.11
- MACD
- CALC -0.12
- SNTI 0.00
- Stochastic Oscillator
- CALC 40.00
- SNTI 13.64
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.